Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma

Journal of the American College of Surgeons

Volumn 188, Issue 5, 1999, Pages 522-530

  Vrouenraets, Bart C ^a   Hart, Guus A M ^a   Eggermont, Alexander M M ^b   Klaase, Joost M ^a   Van Geel, Bert N ^b   Nieweg, Omgo E ^a   Kroon, Bin B R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIMB PERFUSION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TOXICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EDEMA; ERYTHEMA; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON TYPE II; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032926896     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(99)00018-6     Document Type: Article

References (37)

1. Creech O Jr, Krementz ET, Ryan RF, Winblad JW. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-632.
2. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-1328.
3. Hafström L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9:2091-2094.
4. Klaase JM, Kroon BBR, Van Geel AN, et al. Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994; 167:618-620.
5. Thompson JF, Lai DTM, Ingvar C, et al. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4[Suppl 1]:45-50.
6. Liénard D, Lejeune F, Autier PH, et al. Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In: Lejeune FJ, Chaudhuri PK, Das Gupta T, eds. Malignant melanoma: medical and surgical management. New York: McGraw-Hill; 1994:241-248.
7. Thompson JF, Eksborg S, Kam PCA, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996;6:267-271.
8. Vrouenraets BC, Klaase JM, Kroon BBR, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs: the influence of acute regional toxic reactions. Arch Surg 1995;130:43-47.
9. Klaase JM, Kroon BBR, Van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 1994;115:39-45.
10. Klaase JM, Kroon BBR, Van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994;178:564-572.
11. Kroon BBR. Regional isolation perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 1988;14:101-110.
12. Kroon BBR, Klaase JM, Van Geel AN, et al. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993;29A:325-328.
13. Kroon BBR, Klaase JM, Van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992;4:223-226.
14. Kroon BBR, Klaase JM, Van de Merwe SA, et al. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Reg Cancer Treat 1992;4:305-308.
15. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha, interferon-gamma and melphalan for melanoma stage III: results of a multicenter pilot study. Melanoma Res 1994;4[Suppl 1]: 21-26.
16. Wieberdink J, Benckhuijsen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
17. Benckhuijsen C, Kroon BBR, Van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14:157-163.
18. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization; 1979.
19. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34:187-220.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Vrouenraets BC, Kroon BBR, Klaase JM, et al. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995;5:425-431.
22. Vrouenraets BC, Kroon BBR, Klaase JM, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Am Surg Oncol 1997;4:88-94.
23. Klaase JM, Kroon BBR, Van Slooten GW, et al. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat 1992;4: 309-312.
24. Siddik ZH, Edwards MJ, Boddie AW. Isolated limb perfusion with chemotherapeutic agents for melanoma: a reevaluation of drug dosimetry. Eur J Cancer Clin Oncol 1989;25:1393-1397.
25. Ghussen F, Krüger I. Technical aspects of isolation extremity perfusion: experimental studies and clinical experience. J Invest Surg 1989;2:487-496.
26. Krementz ET, Saha S, Limb perfusion with melphalan for melanoma by increased dose and dilution compared to standard technique - a pilot study. Reg Cancer Treat 1989;2:233-237.
27. Atema A, Buurman KJH, Noteboom E, Smets LA. Potentiation of DNA adduct formation and cytotoxicity of platinum-containing drugs by low pH, Int J Cancer 1993;54:166-172.
28. Edwards MJ, Soong S-J, Boddie AW, et al. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch Surg 1990;125:317-321.
29. Scott RN, Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma: bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, eds. Progress in regional cancer therapy. Berlin: Springer-Verlag; 1990: 195-200.
30. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995:31A:1009-1016.
31. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalating study. J Clin Oncol 1996;14:479-489.
32. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: DeVita VT, Hellman S, Rosenburg SA, eds. Important advances in oncology 1994. Philadelphia: JB Lippincott; 1994:179-192.
33. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989;63:2551-2561.
34. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995;19:363-368.
35. Treidman L, McNeer G. Prognosis with local metastases and recurrence in malignant melanoma. Ann N Y Acad Sci 1963; 100:123-130.
36. Krementz ET. Regional perfusion. Current sophistication, what next? Cancer 1986;57:416-432.
37. Sutherland CM, Mather FJ, Krementz ET. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 1987;164:111-118.